Runners-up this week include litigators at Paul Hastings, Williams & Connolly, King & Spalding, McFarland Litigation Partners ...

Goldman Sachs analyst Chris Shibutani maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $136.00.

BioNTech is expanding its oncology pipeline with FixVac, iNeST, and BNT327 for individualized cancer treatments. Read why I ...

The latest analyst coverage could presage a bad day for BioNTech SE (NASDAQ:BNTX), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little ...

So, Novavax doesn't look like an attractive biotech stock right now. Investors should stay away. Prosper Junior Bakiny has no ...

Citigroup started coverage on shares of BioNTech (NASDAQ:BNTX – Free Report) in a report issued on Thursday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $145.00 target ...

President Donald Trump's plan to impose 25% tariffs on goods from the European Union is likely to provoke retaliatory action from the group's 27 member countries and could raise prices for ...

Analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of BioNTech in a research report ...

Fintel reports that on March 13, 2025, Citigroup initiated coverage of BioNTech SE - Depositary Receipt () (NasdaqGS:BNTX) ...

BioNTech SE ( NASDAQ:BNTX ) just released its full-year report and things are looking bullish. Results overall ...

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.

U.S.-listed shares of BioNTech SE ended Monday nearly 3.2% lower, weighed down by a weak full-year revenue projection even as ...